PRESS RELEASES Guest User 8/1/23 Guest User 8/1/23 Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Read More Guest User 6/5/23 Guest User 6/5/23 BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis Read More Guest User 5/15/23 Guest User 5/15/23 BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update Read More Guest User 4/17/23 Guest User 4/17/23 BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update Read More Guest User 3/16/23 Guest User 3/16/23 BiondVax to Present at BIO-Europe Spring Read More Guest User 2/2/23 Guest User 2/2/23 BiondVax Presenting at BIO CEO & Investor Conference Read More Guest User 1/23/23 Guest User 1/23/23 BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study Read More Guest User 1/6/23 Guest User 1/6/23 BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study Read More Guest User 1/5/23 Guest User 1/5/23 BiondVax to Present at Biotech Showcase 2023 Read More Newer Posts
Guest User 8/1/23 Guest User 8/1/23 Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Read More
Guest User 6/5/23 Guest User 6/5/23 BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis Read More
Guest User 5/15/23 Guest User 5/15/23 BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update Read More
Guest User 4/17/23 Guest User 4/17/23 BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update Read More
Guest User 1/23/23 Guest User 1/23/23 BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study Read More
Guest User 1/6/23 Guest User 1/6/23 BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study Read More
